Combustion

NewHydrogen CEO Steve Hill Discussed Use of Hydrogen for Aviation with University of Tennessee Expert

Retrieved on: 
Tuesday, April 9, 2024
Mechanical, Academic Press, Electricity, Paris-Saclay University, Mechanics, Combustion, Associate, National Science Foundation, École Centrale Paris, Airbus, Research, Aviation, University, Carbon, Student, Paris-Sud University, NASA, American Institute, Investment, Society, Hydrogen, Water, Frustration, Doctorate

SANTA CLARITA, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTCMKTS:NEWH), the developer of ThermoLoop™, a breakthrough technology that uses water and heat rather than electricity to produce the world’s cheapest green hydrogen, today announced that in a recent podcast the Company’s CEO Steve Hill spoke with Dr. Paul Palies, Associate Professor at the University of Tennessee Space Institute and founder of the Combustion and Propulsion for Aviation Research Center regarding future aviation based on hydrogen combustion for a decarbonized system.

Key Points: 
  • Dr. Palies said, “There is a need for a clean combustion system that doesn't add nitrogen oxide and completely removes the carbon footprint.
  • Dr. Palies said, “Our team is conducting research on premix combustion, a method that could reduce emissions while maintaining thermal power.
  • Mr. Hill thanked Dr. Palies for his insights, and briefly introduced NewHydrogen’s work on developing thermochemical approaches to affordable green hydrogen.
  • Dr. Paul Palies is Associate Professor at The University of Tennessee Space Institute where he established the Combustion and Propulsion for Aviation Research Center, his research group.

Waste Management Market worth $1598.1 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 8, 2024
Single, Biodegradable waste, Agricultural waste, Glass, Metal, Investment, Restaurant, Republic Services, Hook, Wood, Combustion, Waste management, Food industry, Compost, Developing country, PS, Region, Municipal solid waste, Electricity, PVC, Industrial waste, Hazardous waste, Plastic, L.L.C, Demolition, Mining, Construction, Manure, Environment, Digestion, PET, PP, Process, Collection, Government, Recycling

Based on waste type, the Waste Management Market is categorized into six categories: Hazardous Waste, E-Waste, Municipal Solid Waste, Medical Waste, Construction & Demolition, Non-Hazardous Industrial waste.

Key Points: 
  • Based on waste type, the Waste Management Market is categorized into six categories: Hazardous Waste, E-Waste, Municipal Solid Waste, Medical Waste, Construction & Demolition, Non-Hazardous Industrial waste.
  • Developing countries like China see a rise in industrial waste generation, while countries like India witness increasing demand for waste management services.
  • In North America, the waste management sector benefits from efficient industrial waste management techniques, an increasing focus on environmental cleanliness, and the primary industrial sectors such as electricity, pharmaceuticals, and oil and gas, which are major consumers of waste management services.
  • (US), Suez (France), Veolia (France), Republic Services (US) & Waste Connections (US) are the market leaders in the Waste Management Market.

Waste Management Market worth $1598.1 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, April 8, 2024
Single, Biodegradable waste, Agricultural waste, Glass, Metal, Investment, Restaurant, Republic Services, Hook, Wood, Combustion, Waste management, Food industry, Compost, Developing country, PS, Region, Municipal solid waste, Electricity, PVC, Industrial waste, Hazardous waste, Plastic, L.L.C, Demolition, Mining, Construction, Manure, Environment, Digestion, PET, PP, Process, Collection, Government, Recycling

Based on waste type, the Waste Management Market is categorized into six categories: Hazardous Waste, E-Waste, Municipal Solid Waste, Medical Waste, Construction & Demolition, Non-Hazardous Industrial waste.

Key Points: 
  • Based on waste type, the Waste Management Market is categorized into six categories: Hazardous Waste, E-Waste, Municipal Solid Waste, Medical Waste, Construction & Demolition, Non-Hazardous Industrial waste.
  • Developing countries like China see a rise in industrial waste generation, while countries like India witness increasing demand for waste management services.
  • In North America, the waste management sector benefits from efficient industrial waste management techniques, an increasing focus on environmental cleanliness, and the primary industrial sectors such as electricity, pharmaceuticals, and oil and gas, which are major consumers of waste management services.
  • (US), Suez (France), Veolia (France), Republic Services (US) & Waste Connections (US) are the market leaders in the Waste Management Market.

Merck Manuals Details Key Facts to Know About Multiple Sclerosis

Retrieved on: 
Wednesday, February 7, 2024
Hypoesthesia, Leg, Research, Immune system, MD, Patient, Pain, Neurology, Virus, Confusion, Diagnosis, University of Saskatchewan, Hand, College of Medicine, Brain, Editorial, Multiple sclerosis, Risk, Infection, Combustion, University, Face, System, Spinal cord

The cause of MS is unknown, but some studies point to early exposure to certain viruses in triggering the immune system to attack the body's own tissue.

Key Points: 
  • The cause of MS is unknown, but some studies point to early exposure to certain viruses in triggering the immune system to attack the body's own tissue.
  • Individuals without a formal diagnosis may be tempted to ignore their illness, especially if symptoms have waned, says Levin.
  • But he adds it's crucial to work to uncover the cause of symptoms and discuss them with a healthcare professional.
  • Based on the condition and its symptoms, neurologists can guide patients toward the most effective treatments and medications.

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Oteseconazole, Vaginal discharge, Red, Candidiasis, Capsule, Irritation, CYP, Fluconazole, Yeast, Patient, National Medical Products Administration, Azole, Enzyme, FDA, Candida albicans, Excipient, Dyspareunia, Vaginal yeast infection, Hypersensitivity, Combustion, Fissure, CYP51, Woman, Pharmaceutical industry

DURHAM, N.C., Feb. 7, 2024 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Key Points: 
  • VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
  • "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
  • Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
  • In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Chills, Patient, Medical Subject Headings, Marketing, Lethargy, European Commission, Agency, INN, Allergy, Stinger, ATC, Antibody, Restless, Blood, Bleeding, International, PEG, European, Headache, Haemophilia B, Choroid plexus, Ageing, Nausea, Brain, Language, Profile, Swelling, Haemophilia, Flushing, Combustion, Select, Safety, Anatomy, Medicine, Vomiting, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 5, Status: Authorised

Transforming to FutureCoal: The Global Alliance for Sustainable Coal

Retrieved on: 
Tuesday, November 21, 2023
Rehabilitation, CTL, NOx, SCS, Sulfur oxide, Flue-gas desulfurization, Recycling, Cogeneration, Combustion, Combined cycle power plant, IGCC, Health, Electricity, ESP, Coal, Waste management, Heart, HELE, Global Alliance, Biomass, Hydrogen, CHP, Methanol, Carbon, Safety, Steel, FGD, CO2, Dust, USC, Renewable energy

The FutureCoal Global Alliance is the world's only multi-lateral, neutral and progressive organisation representing the entire coal value chain which is dedicated to raising awareness on the significant total contribution of coal.

Key Points: 
  • The FutureCoal Global Alliance is the world's only multi-lateral, neutral and progressive organisation representing the entire coal value chain which is dedicated to raising awareness on the significant total contribution of coal.
  • The Global Alliance educates on the critical resource coal and its immense and continued involvement in bettering the lives and livelihoods of our global community.
  • The Alliance recognises that as an integrated coal value chain, we must serve to support both economic and environmental national and international ambitions.
  • Sustainable Coal Stewardship (SCS) provides a pathway which supports extracting more value per tonne of coal.

Dr. Wolff's Vagisan Introduces Hormone-Free Moisturising Cream and Moisturising Cremolum, Clinically Proven to Soothe Vaginal Dryness

Retrieved on: 
Thursday, October 19, 2023
Cream, Lubrication, Vaginal discharge, Ageing, Menopause, Family, Vagina, Itch, Skin, Combustion, Friends, Climacteric, AIP, Quality of life, Lipid, International Menopause Society, Risk, Moisturizer, Dry, Woman, Safety, Elasticity, Personal lubricant, Pain, Douche, Kong, Birth control

Hong Kong SAR, China--(Newsfile Corp. - October 19, 2023) - Dr. Wolff's Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum for women troubled by vaginal dryness while experiencing menopause.

Key Points: 
  • Hong Kong SAR, China--(Newsfile Corp. - October 19, 2023) - Dr. Wolff's Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum for women troubled by vaginal dryness while experiencing menopause.
  • Vaginal secretions gradually decrease as a woman ages, resulting in decreased lubrication and elasticity of the vaginal tissue.
  • This can result in vaginal dryness and associated symptoms such as dryness, itching, burning, and pain3.
  • Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.

Dr. Wolff Group: Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness

Retrieved on: 
Thursday, October 26, 2023
Cream, Lubrication, Vaginal discharge, Ageing, Menopause, Family, Itch, Skin, Combustion, Vagina, Friends, Climacteric, AIP, Quality of life, Lipid, International Menopause Society, Risk, Moisturizer, Dry, Woman, Safety, Elasticity, SAR, Personal lubricant, Pain, Douche, Birth control, Cosmetics

Dr. Wolff Group: Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness

Key Points: 
  • Dr. Wolff Group: Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness
    The issuer is solely responsible for the content of this announcement.
  • Dr. Wolff’s Vagisan introduces hormone-free Moisturising Cream and Moisturising Cremolum, clinically proven to soothe vaginal dryness
    HONG KONG SAR - Media OutReach - 18 October 2023 - Many woman experiencing menopause are troubled by vaginal dryness.
  • This can result in vaginal dryness and associated symptoms such as dryness, itching, burning, and pain3.
  • Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.